Trazodone 250mg is NOT recommended as a first-line treatment for depression, though it can be effective at this dose when used appropriately
The American Academy of Sleep Medicine explicitly recommends AGAINST using trazodone for depression treatment as a primary option 1. While trazodone is FDA-approved for major depressive disorder (MDD) 2, the evidence supporting its efficacy is weak compared to other antidepressants, and clinical guidelines consistently place it lower in treatment algorithms.
Evidence Quality and Positioning
The 2017 AASM Clinical Practice Guideline provides a conditional recommendation AGAINST trazodone for insomnia based on trials of 50mg doses, citing insufficient evidence 1. While this guideline focused on insomnia rather than depression, it reflects the overall weak evidence base for trazodone.
For depression specifically:
- Trazodone is FDA-approved for MDD treatment 2
- The typical antidepressant dose range is 150-300mg daily 3, making 250mg within the therapeutic range
- However, multiple guidelines position trazodone as a third-line option, recommended only after benzodiazepine receptor agonists fail and primarily when comorbid depression/anxiety exists 3
When Trazodone 250mg May Be Appropriate
Consider trazodone 250mg for depression when:
- First-line SSRIs or SNRIs have failed or caused intolerable side effects
- The patient has comorbid insomnia requiring treatment 3
- Sexual dysfunction from SSRIs is problematic (trazodone has lower risk) 4
- The patient cannot tolerate anticholinergic effects of tricyclics 5
Research evidence shows trazodone 250mg can be effective - one comparative trial found it equivalent to fluoxetine for depression, with the median sustained dose being exactly 250mg 6. Long-term studies demonstrate continued efficacy over 12 months 5.
Critical Dosing Considerations
The 250mg dose should be:
- Taken shortly after a meal or light snack to optimize absorption 2
- Built up gradually from lower starting doses
- Monitored for orthostatic hypotension, especially in elderly patients 3
- Assessed for drowsiness/sedation that may require dose timing adjustment 2
Comparative Effectiveness
Recent research suggests trazodone extended-release may produce larger effect sizes than SSRIs across depression, anxiety, and sleep domains 7. However, this represents newer formulation data not yet incorporated into major guidelines.
The 2023 American College of Physicians systematic review found similar benefits among most antidepressants as first-step treatments, but noted low certainty of evidence for most comparisons 8. This equipoise supports individualized selection based on side effect profiles rather than efficacy alone.
Safety Warnings
Monitor for:
- Orthostatic hypotension - particularly dangerous in elderly or those with cardiovascular disease 3
- QT prolongation - dose-dependent risk of cardiac arrhythmias 9, 4
- Priapism - rare but serious adverse effect requiring immediate attention 2, 4
- Suicidal ideation - standard monitoring for all antidepressants, especially in young adults 2
Contraindications
Do not use trazodone if:
- Taking MAOIs or within 2 weeks of MAOI discontinuation 2
- Severe hepatic impairment present
- History of priapism
Bottom Line Algorithm
For treating depression with trazodone 250mg:
- First, try: SSRIs (escitalopram, sertraline) or SNRIs (venlafaxine, duloxetine) as first-line per standard guidelines
- If first-line fails or causes sexual dysfunction/insomnia: Consider trazodone 150-300mg
- Start low: Begin at 50-100mg and titrate up to 250mg over 2-4 weeks
- Take with food: Shortly after meals to reduce side effects and improve absorption
- Monitor closely: Blood pressure (especially orthostatic), cardiac function if risk factors present, and suicidality in first 4-8 weeks
- Assess response: Allow 4-6 weeks at therapeutic dose before determining efficacy
- If partial response: Can increase to 300mg or augment with psychotherapy
The evidence supports trazodone 250mg as an effective antidepressant dose, but it should not be your first choice - reserve it for patients who have failed or cannot tolerate first-line agents, or when comorbid insomnia makes its sedating properties advantageous 3, 1.